Cargando…

Cerebrospinal Fluid PKR Level Predicts Cognitive Decline in Alzheimer’s Disease

The cerebrospinal fluid (CSF) levels of the proapoptotic kinase R (PKR) and its phosphorylated PKR (pPKR) are increased in Alzheimer’s disease (AD), but whether CSF PKR concentrations are associated with cognitive decline in AD patients remain unknown. In this study, 41 consecutive patients with AD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dumurgier, Julien, Mouton-Liger, Francois, Lapalus, Pauline, Prevot, Magali, Laplanche, Jean-Louis, Hugon, Jacques, Paquet, Claire
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539966/ https://www.ncbi.nlm.nih.gov/pubmed/23320095 http://dx.doi.org/10.1371/journal.pone.0053587

Ejemplares similares

PKR involvement in Alzheimer’s disease
por: Hugon, Jacques, et al.
Publicado: (2017)

Blood-Based Kinase Assessments in Alzheimer’s Disease
por: Hugon, Jacques, et al.
Publicado: (2018)

Pro-Apoptotic Kinase Levels in Cerebrospinal Fluid as Potential Future Biomarkers in Alzheimer’s Disease
por: Paquet, Claire, et al.
Publicado: (2015)

Cerebrospinal Fluid Alpha-Synuclein Improves the Differentiation between Dementia with Lewy Bodies and Alzheimer’s Disease in Clinical Practice
por: Lilamand, Matthieu, et al.
Publicado: (2022)

Peripheral inflammation increases PKR activation, Tau phosphorylation and amyloid β production in wild-type mice
por: Mouton-Liger, François, et al.
Publicado: (2013)

Neuroprotective role of PKR in a model of neurodegeneration due to mild impairment of oxidative metabolism
por: Mouton-Liger, François, et al.
Publicado: (2013)

PKR downregulation prevents neurodegeneration and β-amyloid production in a thiamine-deficient model
por: Mouton-Liger, F, et al.
Publicado: (2015)

Biomarker profiles of Alzheimer’s disease and dynamic of the association between cerebrospinal fluid levels of β-amyloid peptide and tau
por: Lafirdeen, Aysha S. Mohamed, et al.
Publicado: (2019)

PKR knockout in the 5xFAD model of Alzheimer's disease reveals beneficial effects on spatial memory and brain lesions
por: Tible, Marion, et al.
Publicado: (2019)

PKR modulates abnormal brain signaling in experimental obesity
por: Taga, Mariko, et al.
Publicado: (2018)

CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer’s disease
por: Mouton-Liger, François, et al.
Publicado: (2020)

The PKR/P38/RIPK1 Signaling Pathway as a Therapeutic Target in Alzheimer’s Disease
por: Hugon, Jacques, et al.
Publicado: (2021)

Full-length and C-terminal neurogranin in Alzheimer’s disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays
por: Öhrfelt, Annika, et al.
Publicado: (2020)

Plasma neuregulin 1 as a synaptic biomarker in Alzheimer’s disease: a discovery cohort study
por: Vrillon, Agathe, et al.
Publicado: (2022)

Are ketogenic diets promising for Alzheimer’s disease? A translational review
por: Lilamand, Matthieu, et al.
Publicado: (2020)

A diagnostic scale for Alzheimer’s disease based on cerebrospinal fluid biomarker profiles
por: Lehmann, Sylvain, et al.
Publicado: (2014)

Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study
por: Dumurgier, Julien, et al.
Publicado: (2015)

Neuroinflammation and Aβ Accumulation Linked To Systemic Inflammation Are Decreased By Genetic PKR Down-Regulation
por: Carret-Rebillat, Anne-Sophie, et al.
Publicado: (2015)

Copper and zinc isotopic excursions in the human brain affected by Alzheimer's disease
por: Moynier, Frédéric, et al.
Publicado: (2020)

New highly sensitive rodent and human tests for soluble amyloid precursor protein alpha quantification: preclinical and clinical applications in Alzheimer’s disease
por: Rose, Christiane, et al.
Publicado: (2012)

CSF level of β-amyloid peptide predicts mortality in Alzheimer’s disease
por: Boumenir, Adla, et al.
Publicado: (2019)

Cerebrospinal fluid A beta 1–40 peptides increase in Alzheimer’s disease and are highly correlated with phospho-tau in control individuals
por: Lehmann, Sylvain, et al.
Publicado: (2020)

What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France
por: Cognat, Emmanuel, et al.
Publicado: (2019)

Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker–based case–control study
por: Saddiki, Hana, et al.
Publicado: (2020)

Efficacy and Safety of Ketone Supplementation or Ketogenic Diets for Alzheimer's Disease: A Mini Review
por: Lilamand, Matthieu, et al.
Publicado: (2022)

The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer’s disease
por: Öhrfelt, Annika, et al.
Publicado: (2016)

Utility of CSF biomarkers in psychiatric disorders: a national multicentre prospective study
por: Paquet, Claire, et al.
Publicado: (2016)

Impact of pain on cognitive functions in primary Sjögren syndrome with small fiber neuropathy: 10 cases and a literature review
por: Indart, Sandrine, et al.
Publicado: (2017)

Cerebrospinal Fluid Cortisol and Dehydroepiandrosterone Sulfate, Alzheimer’s Disease Pathology, and Cognitive Decline
por: Ouanes, Sami, et al.
Publicado: (2022)

Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia
por: Llorens, Franc, et al.
Publicado: (2020)

Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum
por: Benedet, Andréa L., et al.
Publicado: (2021)

Cerebrospinal Fluid Proteome Alterations Associated with Neuropsychiatric Symptoms in Cognitive Decline and Alzheimer’s Disease
por: Mroczek, Magdalena, et al.
Publicado: (2022)

PKR, the double stranded RNA-dependent protein kinase as a critical target in Alzheimer's disease
por: Morel, Milena, et al.
Publicado: (2009)

Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview
por: Delaby, Constance, et al.
Publicado: (2021)

SNPs Associated with Cerebrospinal Fluid Phospho-Tau Levels Influence Rate of Decline in Alzheimer's Disease
por: Cruchaga, Carlos, et al.
Publicado: (2010)

Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer’s disease
por: Cicognola, Claudia, et al.
Publicado: (2018)

Cognitive decline and brainstem hypometabolism in long COVID: A case series
por: Hugon, Jacques, et al.
Publicado: (2022)

The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer’s Disease
por: De Vos, Ann, et al.
Publicado: (2016)

Low Cerebrospinal Fluid Levels of Hemopexin Are Associated With Increased Alzheimer's Pathology, Hippocampal Hypometabolism, and Cognitive Decline
por: Ashraf, Azhaar A., et al.
Publicado: (2020)

Ten-Year Trends in Sales of Alzheimer Disease Drugs in France Compared With Sales in Germany, Spain, and the UK
por: Ben Hassen, Céline, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9hg8drdbk2j7n000o1fjide8am